Create Alert
Sign Up
Sign In
Sign In
Sign Up
Contact Us
Careers
Terms and Conditions
Privacy
About Us
Home
Livefeed
Market Data
Companies
Filings
Ownership Search
Mutual Fund Search
Watchlist
My Watchlist
Create Alerts to view your Watchlist
Live Feed
Feed to the latest filings at the SEC
Type of Filers
All
Mutual Funds
Mutual 3 & ETFs
Mutual 2 & ETFs
Variable Insurance Products
Variable Insurance 1
Variable Insurance 3
Variable Insurance 4
Type of Forms
All
Annual Reports
10-K
10-K/A
18-K
20-F
20-F/A
24F-2NT
24F-2NT/A
40FR12B
MA/A
MA-I
MA-I/A
N-CSR
NSAR-B
NSAR-B/A
NT 10-K
TA-2/A
Quarterly Reports
10-Q
10-Q/A
N-Q
Proxy Statements
DEF 14 A
DEF 14C
DEFA14A
DEFC14A
DEFM14A
DFAN14A
N-PX/A
PRE 14 A
PRE 14C
PREC14A
PREM14A
PRER14A
PRRN14A
PX14A6G
Prospectus
425
POS AM
Current-Reports
8-K
8-K/A
Registrations
10-12B
10-12B/A
10-12G
10-12G/A
18-12B
18-12B/A
18-12G
18-12G/A
20FR12B
20FR12B/A
20FR12G
20FR12G/A
24F-2NT
24F-2NT/A
424A
424B1
424B2
424B3
424B4
424B5
424B7
485A24E
485BPOS
486BPOS
487
8-A12B
8-A12B/A
18-12G/A
8-A12G
8-A12G/A
DEL AM
F-1
F-1/A
F-1MEF
F-3
F-3/A
F-3DPOS
F-4
F-4/A
F-6
F-6/A
F-6 POS
N-1
N-14
N-14/A
N-1A
N-1/A
N-1A/A
N-2
N-2MEF
N-3
N-3/A
N-4
N-4/A
N-5
N-54A
N-54A/A
N-5/A
N-8A
N-8A/A
N-8B-2
N-8B-2/A
N-8B-4
N-8B-4/A
POS462B
POS462C
POS 8C
POS AM
POS AMI
POS EX
S-11
S-11/A
S-11MEF
S-1/A
S-1MEF
S-20
S-20/A
S-3
S-3/A
S-3D
S-3DPOS
S-3MEF
S-4EF
S-4MEF
S-4 POS
S-6
S-6/A
S-8
S-8 POS
Date Range
All
One Day Prior
Two Day Prior
Three Day Prior
COGNITION THERAPEUTICS INC
Date Filed :
Oct 15, 2021
View Exhibits
SEC FORM 4
SEC Form 4
FORM 4
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response:
0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
1. Name and Address of Reporting Person
*
Fletcher Aaron G.L.
(Last)
(First)
(Middle)
C/O COGNITION THERAPEUTICS, INC.,
2500 WESTCHESTER AVE.,
(Street)
PURCHASE
NY
10577
(City)
(State)
(Zip)
2. Issuer Name
and
Ticker or Trading Symbol
COGNITION THERAPEUTICS INC
[
CGTX
]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X
Director
10% Owner
Officer (give title below)
Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/13/2021
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X
Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)
2. Transaction Date (Month/Day/Year)
2A. Deemed Execution Date, if any (Month/Day/Year)
3. Transaction Code (Instr. 8)
4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code
V
Amount
(A) or (D)
Price
Common Stock
10/13/2021
C
1,424,014
A
(1)
1,424,014
I
By Bios Memory SPV I, LP.
Common Stock
10/13/2021
C
418,926
A
(1)
418,926
I
By Bios Fund I, LP.
Common Stock
10/13/2021
C
245,029
A
(1)
245,029
I
By Bios Fund I, QP, LP.
Common Stock
10/13/2021
C
78,298
A
(2)
78,298
I
By Bios Fund II, LP.
Common Stock
10/13/2021
C
255,765
A
(2)
255,765
I
By Bios Fund II, QP, LP.
Common Stock
10/13/2021
C
34,238
A
(2)
34,238
I
By Bios Fund II, NT, LP.
Common Stock
10/13/2021
P
23,341
A
$
12
57,579
I
By Bios Fund II, NT, LP.
Common Stock
10/13/2021
C
351,844
A
(2)
351,844
I
By Bios Memory SPV II, LP.
Common Stock
10/13/2021
X
33,495
A
$
0.032
385,339
I
By Bios Memory SPV II, LP.
Common Stock
10/13/2021
S
(3)
90.28
D
$
12
385,248
I
By Bios Memory SPV II, LP.
Common Stock
10/13/2021
C
41,620
A
(2)
41,620
I
By Bios Fund III, LP.
Common Stock
10/13/2021
C
24,263
A
(3)
(5)
65,883
I
By Bios Fund III, LP.
Common Stock
10/13/2021
P
22,129
A
$
12
88,012
I
By Bios Fund III, LP.
Common Stock
10/13/2021
C
596,899
A
(2)
596,899
I
By Bios Fund III, QP, LP.
Common Stock
10/13/2021
C
158,476
A
(5)
755,375
I
By Bios Fund III, QP, LP.
Common Stock
10/13/2021
P
144,530
A
$
12
899,905
I
By Bios Fund III, QP, LP.
Common Stock
10/13/2021
C
34,472
A
(2)
34,472
I
By Bios Fund III, NT, LP.
Common Stock
10/13/2021
C
25,593
A
(5)
60,065
I
By Bios Fund III, NT, LP.
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)
2. Conversion or Exercise Price of Derivative Security
3. Transaction Date (Month/Day/Year)
3A. Deemed Execution Date, if any (Month/Day/Year)
4. Transaction Code (Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date (Month/Day/Year)
7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)
8. Price of Derivative Security (Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code
V
(A)
(D)
Date Exercisable
Expiration Date
Title
Amount or Number of Shares
Series B Convertible Preferred Stock
(1)
10/13/2021
C
4,605,985
(1)
(1)
Common Stock
1,424,014
$
0
0
D
Series B Convertible Preferred Stock
(1)
10/13/2021
C
1,355,017
(1)
(1)
Common Stock
418,926
$
0
0
I
By Bios Fund I, LP.
Series B Convertible Preferred Stock
(1)
10/13/2021
C
792,547
(1)
(1)
Common Stock
245,029
$
0
0
I
By Bios Fund I, QP, LP.
Series B-1 Convertible Preferred Stock
(2)
10/13/2021
C
253,256
(2)
(2)
Common Stock
78,298
$
0
0
I
By Bios Fund II, LP.
Series B-1 Convertible Preferred Stock
(2)
10/13/2021
C
827,275
(2)
(2)
Common Stock
255,765
$
0
0
I
By Bios Fund II, QP, LP.
Series B-1 Convertible Preferred Stock
(2)
10/13/2021
C
1,138,040
(2)
(2)
Common Stock
351,844
$
0
0
I
By Bios Memory SPV II, LP.
Series B-1 Convertible Preferred Stock
(2)
10/13/2021
C
110,744
(2)
(2)
Common Stock
34,238
$
0
0
I
By Bios Fund II, NT, LP.
Series B-1 Convertible Preferred Stock
(2)
10/13/2021
C
134,626
(2)
(2)
Common Stock
41,620
$
0
0
I
By Bios Fund III, LP.
Series B-1 Convertible Preferred Stock
(2)
10/13/2021
C
1,930,673
(2)
(2)
Common Stock
596,899
$
0
0
I
By Bios Fund III, QP, LP.
Series B-1 Convertible Preferred Stock
(2)
10/13/2021
C
111,504
(2)
(2)
Common Stock
34,472
$
0
0
I
By Bios Fund III, NT, LP.
Warrant (right to buy)
$
0.032
10/13/2021
X
33,495
03/15/2016
(4)
03/15/2023
(4)
Common Stock
33,495
$
0
0
I
By Bios Memory SPV II, LP.
Simple Agreement for Future Equity
(5)
10/13/2021
C
24,263
(5)
(5)
Common Stock
$
232,933.33
$
0
0
I
By Bios Fund III, LP.
Simple Agreement for Future Equity
(5)
10/13/2021
C
158,476
(5)
(5)
Common Stock
$
1,521,373.34
$
0
0
I
By Bios Fund III, QP, LP.
Simple Agreement for Future Equity
(5)
10/13/2021
C
25,593
(5)
(5)
Common Stock
$
245,693.33
$
0
0
I
By Bios Fund III, NT, LP.
Explanation of Responses:
1. The Series B Convertible Preferred Stock converted into Cognition Therapeutics, Inc. ("CGTX") common stock upon the closing of the issuer's initial public offering ("IPO"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration.
2. The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration.
3. On October 13, 2021, the reporting person exercised a warrant to purchase 33,495 shares of CGTX common stock for $0.032 per share. The reporting person paid the exercise price on a cashless basis, resulting in CGTX's withholding of 90.28 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 33,404 shares. The issuer paid cash to the reporting person in lieu of any fractional share amounts.
4. The warrant expires on the earliest of (i) March 15, 2023, (ii) upon a liquidation, dissolution or winding up of the Company, (iii) the closing of a Sale Transaction (as defined in the warrant), (iv) upon the closing of the issuer's IPO or (v) upon repayment of a promissory note issued in connection with the warrant.
5. The Simple Agreement for Future Equity converted into CGTX common stock upon the closing of the issuer's IPO at 80% of the per share offering price of the IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration.
By: /s/ Aaron Fletcher
10/15/2021
** Signature of Reporting Person
Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person,
see
Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Stock View
Indices
by TradingView
